Organon

Lawrence Eichenfield, MD, discussed recent FDA approvals: tapinarof cream, 1% for AD in patients 2 years and older, and nemolizumab for moderate-to-severe AD in patients 12 years and up. Both treatments offer non-steroidal alternatives, with tapinarof providing a favorable safety profile and nemolizumab targeting IL-31, offering potential unique responses.

FDA approves Organon's Vtama cream for atopic dermatitis in adults and children aged 2+. Approval based on positive phase 3 ADORING trials showing significant skin clearance and itch reduction. Vtama offers potential for powerful skin clearance without label warnings or restrictions.

The FDA approved Organon’s Vtama cream for atopic dermatitis in adults and children aged 2 and older, offering a steroid-free option with no label warnings or restrictions. Approval was based on ADORING trials, showing significant improvement in skin clearance. Common adverse events were mild.

The FDA approved Organon's VTAMA cream, 1%, for treating atopic dermatitis in adults and children aged 2 and older, offering potential skin clearance without restrictions.

FDA approved Vtama cream 1% for atopic dermatitis in adults & children aged 2+. ADORING trials showed nearly 50% achieved clear skin vs 14% placebo after 8 weeks. Long-term study confirmed safety & effectiveness over 48 weeks. Vtama addresses underrepresentation in dermatology research & is also approved for plaque psoriasis.

FDA approves Vtama cream 1% for atopic dermatitis in adults and children aged 2+. Vtama, a nonsteroidal topical treatment, showed significant itch reduction and skin clearance in phase 3 trials.

FDA approves Vtama (tapinarof) cream for atopic dermatitis in adults and children 2+ years, offering potential for powerful skin clearance without restrictions on duration or body surface area affected. Vtama cream demonstrated significant improvements in AD symptoms in pivotal studies, with a safety profile consistent with short-term use.

The FDA approved tapinarof cream, 1% (Vtama; Organon) for atopic dermatitis in patients aged 2+ based on positive ADORING 1, 2, and 3 trial data. The cream showed rapid itch relief, significant improvement in AD scores, and was well-tolerated with common adverse effects. Organon's CEO highlighted the therapy's potential for powerful skin clearance without restrictions. The approval reaffirms Organon's commitment to addressing unmet needs in AD treatment.

The FDA approved tapinarof cream 1% (VTAMA; Organon) for treating atopic dermatitis in patients aged 2 and older, based on ADORING trials showing efficacy across all skin types. Tapinarof, an aryl hydrocarbon receptor agonist, demonstrated significant improvements in primary and secondary endpoints, with common adverse reactions including upper respiratory tract infection, folliculitis, and lower respiratory tract infection.

The FDA approved tapinarof (Vtama) cream 1% for atopic dermatitis in patients aged 2 years and older. The approval, announced by Organon, follows positive ADORING trial results, showing significant improvements in skin condition and itch reduction. Tapinarof cream is an aryl hydrocarbon receptor agonist, offering relief for children as young as 2.